Skip to main content
Top

Breast Cancer Research and Treatment

Issue 2/2013

Content (33 Articles)

Review

Is mammographic density differentially associated with breast cancer according to receptor status? A meta-analysis

Sebastien Antoni, Annie J. Sasco, Isabel dos Santos Silva, Valerie McCormack

Review

Trastuzumab administration during pregnancy: a systematic review and meta-analysis

Flora Zagouri, Theodoros N. Sergentanis, Dimosthenis Chrysikos, Christos A. Papadimitriou, Meletios-Athanassios Dimopoulos, Rupert Bartsch

Preclinical Study

Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism

Jennifer L. Allensworth, Scott J. Sauer, H. Kim Lyerly, Michael A. Morse, Gayathri R. Devi

Preclinical study

MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion

Jessica Bockhorn, Kathy Yee, Ya-Fang Chang, Aleix Prat, Dezheng Huo, Chika Nwachukwu, Rachel Dalton, Simo Huang, Kaitlin E. Swanson, Charles M. Perou, Olufunmilayo I. Olopade, Michael F. Clarke, Geoffrey L. Greene, Huiping Liu

Preclinical study

Vimentin DNA methylation predicts survival in breast cancer

Jacob Ulirsch, Cheng Fan, George Knafl, Ming Jing Wu, Brett Coleman, Charles M. Perou, Theresa Swift-Scanlan

Open Access Preclinical Study

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

Josefine Bostner, Elin Karlsson, Muneeswaran J. Pandiyan, Hanna Westman, Lambert Skoog, Tommy Fornander, Bo Nordenskjöld, Olle Stål

Preclinical Study

Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes

Lars C. Hanker, Achim Rody, Uwe Holtrich, Lajos Pusztai, Eugen Ruckhaeberle, Cornelia Liedtke, Andre Ahr, Tomas M. Heinrich, Nicole Sänger, Sven Becker, Thomas Karn

Preclinical Study

Differential expression of immune-related markers in breast cancer by molecular phenotypes

Junjeong Choi, Do Hee Kim, Woo Hee Jung, Ja Seung Koo

Preclinical Study

Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features

Purevsuren Jambal, Melanie M. Badtke, J. Chuck Harrell, Virginia F. Borges, Miriam D. Post, Grace E. Sollender, Monique A. Spillman, Kathryn B. Horwitz, Britta M. Jacobsen

Clinical trial

Effect of HER2 status on distant recurrence in early stage breast cancer

Kenneth R. Hess, Francisco J. Esteva

Open Access Clinical Trial

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

Denise A. Yardley, Lowell Hart, Linda Bosserman, Mansoor N. Salleh, David M. Waterhouse, Maura K. Hagan, Paul Richards, Michelle L. DeSilvio, Janine M. Mahoney, Yasir Nagarwala

Clinical trial

Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients

Holm Eggemann, Atanas Ignatov, Bobbie J. Smith, Udo Altmann, Gunter von Minckwitz, Freidrich W. Röhl, Mark Jahn, Serban-Dan Costa

Open Access Clinical Trial

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

Massimo Cristofanilli, Stephen R. D. Johnston, Alexey Manikhas, Henry L. Gomez, Oleg Gladkov, Zhimin Shao, Sufia Safina, Kimberly L. Blackwell, Ricardo H. Alvarez, Stephen D. Rubin, Sulabha Ranganathan, Suman Redhu, Maureen E. Trudeau

Open Access Clinical trial

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

Cynthia X. Ma, Matthew J. C. Ellis, Gina R. Petroni, Zhanfang Guo, Shi-rong Cai, Christine E. Ryan, A. Craig Lockhart, Michael J. Naughton, Timothy J. Pluard, Christiana M. Brenin, Joel Picus, Allison N. Creekmore, Tibu Mwandoro, Erin R. Yarde, Jerry Reed, Mark Ebbert, Philip S. Bernard, Mark Watson, Laurence A. Doyle, Janet Dancey, Helen Piwnica-Worms, Paula M. Fracasso

Clinical Trial

Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage

Susan K. Conroy, Brenna C. McDonald, Dori J. Smith, Lyndsi R. Moser, John D. West, Lisa M. Kamendulis, James E. Klaunig, Victoria L. Champion, Frederick W. Unverzagt, Andrew J. Saykin

Clinical trial

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer

Markus Wallwiener, Andreas Daniel Hartkopf, Irène Baccelli, Sabine Riethdorf, Sarah Schott, Klaus Pantel, Frederik Marmé, Christof Sohn, Andreas Trumpp, Brigitte Rack, Bahriye Aktas, Erich-Franz Solomayer, Volkmar Müller, Wolfgang Janni, Andreas Schneeweiss, Tanja Natascha Fehm

Epidemiology

Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations

Darya Prokofyeva, Natalia Bogdanova, Natalia Dubrowinskaja, Marina Bermisheva, Zalina Takhirova, Natalia Antonenkova, Nurzhan Turmanov, Ihor Datsyuk, Shamil Gantsev, Hans Christiansen, Tjoung-Won Park-Simon, Peter Hillemanns, Elza Khusnutdinova, Thilo Dörk

Epidemiology

Total energy intake and breast cancer risk in sisters: the Breast Cancer Family Registry

Fang Fang Zhang, Esther M. John, Julia A. Knight, Manleen Kaur, Mary Daly, Saundra Buys, Irene L. Andrulis, Beth Stearman, Dee West, Mary Beth Terry

Epidemiology

Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis

Noel Pabalan, Hamdi Jarjanazi, Hilmi Ozcelik

Epidemiology

Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population

Lilian Jara, Patricio Gonzalez-Hormazabal, Kerube Cerceño, Gabriella A. Di Capua, Jose M. Reyes, Rafael Blanco, Teresa Bravo, Octavio Peralta, Fernando Gomez, Enrique Waugh, Sonia Margarit, Gladys Ibañez, Carmen Romero, Janara Pakomio, Gigia Roizen

Epidemiology

Impact of breast cancer on anti-mullerian hormone levels in young women

H. I. Su, S. W. Flatt, L. Natarajan, A. DeMichele, A. Z. Steiner

Epidemiology

Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20–44 years of age

Christopher I. Li, Elisabeth F. Beaber, Mei-Tzu Chen Tang, Peggy L. Porter, Janet R. Daling, Kathleen E. Malone

Epidemiology

Mind the gap: racial differences in breast cancer incidence and biologic phenotype, but not stage, among low-income women participating in a government-funded screening program

Joan E. Cunningham, Christine A. Walters, Elizabeth G. Hill, Marvella E. Ford, Tiffany Barker-Elamin, Charles L. Bennett

Epidemiology

One-day core needle biopsy in a breast clinic: 4 years experience

Joris P. Bulte, Lenny Polman, Margrethe Schlooz-Vries, Annelies Werner, Renate Besselink, Kelly Sessink, Roel Mus, Susanne Lardenoije, Mechli Imhof-Tas, Johan Bulten, Adriana C. H. van Engen-van Grunsven, Ewout Schaafsma, Luc J. A. Strobbe, Peter Bult, Johannes H. W. De Wilt

Epidemiology

Pain in long-term breast cancer survivors: the role of body mass index, physical activity, and sedentary behavior

Laura P. Forsythe, Catherine M. Alfano, Stephanie M. George, Anne McTiernan, Kathy B. Baumgartner, Leslie Bernstein, Rachel Ballard-Barbash

Epidemiology

Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer

Windy Dean-Colomb, Kenneth R. Hess, Elliana Young, Terrie G. Gornet, Beverly C. Handy, Stacy L. Moulder, Nuhad Ibrahim, Lajos Pusztai, Daniel Booser, Vicente Valero, Gabriel N. Hortobagyi, Francisco J. Esteva

Epidemiology

PTP1B expression is an independent positive prognostic factor in human breast cancer

S. Soysal, E. C. Obermann, F. Gao, D. Oertli, W. E. Gillanders, C. T. Viehl, S. Muenst

Letter to the Editor

Unincluded subjects need to be included for concerning the real association between TNFa−308 G/A polymorphism and cancer susceptibility

Guoqiang Zhang, Zengyan Liu, Xilong Wang, Zhongming Jia, Yong Han, Ye Bi, ShuJian Xu, Kai Cheng, Weiwei Zou, Zhenlin Yang

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine